News & Events

Immunovaccine Initiates Clinical Trial with DPX-RSV Vaccine

Halifax, Nova Scotia; June 30, 2015 – Immunovaccine Inc. , a clinical stage vaccine and immunotherapy company, today announced that it has enrolled the first healthy adult volunteer in a Phase 1 clinical study of its respiratory syncytial virus (RSV) vaccine.

The Phase 1 study will evaluate the safety and immune response profile of the DPX-RSV vaccine candidate in healthy adults. The study, conducted at the Canadian Center for Vaccinology (CCfV) in Halifax and led by Joanne Langley, M.D., will enroll 40 healthy adults who are 50 to 64 years of age. Read More…